Jill Woloszynek
Washington University in St. Louis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jill Woloszynek.
Journal of Experimental Medicine | 2011
Matthew J. Christopher; Mahil Rao; Fulu Liu; Jill Woloszynek; Daniel C. Link
Expression of the G-CSF receptor on bone marrow monocytes is sufficient to trigger HSC mobilization in response to G-CSF, in part via effects on osteoblast lineage cells.
Cancer Research | 2009
Yuval Shaked; Terence Tang; Jill Woloszynek; Laura M.G. Daenen; Shan Man; Ping Xu; Shi Rong Cai; Jeffrey M. Arbeit; Emile E. Voest; David J. Chaplin; Jon Smythe; Adrian L. Harris; Paul Nathan; Ian Judson; Gordon Rustin; Francesco Bertolini; Daniel C. Link; Robert S. Kerbel
Vascular disrupting agents (VDA) cause acute shutdown of abnormal established tumor vasculature, followed by massive intratumoral hypoxia and necrosis. However, a viable rim of tumor tissue invariably remains from which tumor regrowth rapidly resumes. We have recently shown that an acute systemic mobilization and homing of bone marrow-derived circulating endothelial precursor (CEP) cells could promote tumor regrowth following treatment with either a VDA or certain chemotherapy drugs. The molecular mediators of this systemic reactive host process are unknown. Here, we show that following treatment of mice with OXi-4503, a second-generation potent prodrug derivative of combretastatin-A4 phosphate, rapid increases in circulating plasma vascular endothelial growth factor, stromal derived factor-1 (SDF-1), and granulocyte colony-stimulating factor (G-CSF) levels are detected. With the aim of determining whether G-CSF is involved in VDA-induced CEP mobilization, mutant G-CSF-R(-/-) mice were treated with OXi-4503. We found that as opposed to wild-type controls, G-CSF-R(-/-) mice failed to mobilize CEPs or show induction of SDF-1 plasma levels. Furthermore, Lewis lung carcinomas grown in such mice treated with OXi-4503 showed greater levels of necrosis compared with tumors treated in wild-type mice. Evidence for rapid elevations in circulating plasma G-CSF, vascular endothelial growth factor, and SDF-1 were also observed in patients with VDA (combretastatin-A4 phosphate)-treated cancer. These results highlight the possible effect of drug-induced G-CSF on tumor regrowth following certain cytotoxic drug therapies, in this case using a VDA, and hence G-CSF as a possible therapeutic target.
Blood | 2012
Adam M. Greenbaum; Leila Revollo; Jill Woloszynek; Roberto Civitelli; Daniel C. Link
There is evidence suggesting that N-cadherin expression on osteoblast lineage cells regulates hematopoietic stem cell (HSC) function and quiescence. To test this hypothesis, we conditionally deleted N-cadherin (Cdh2) in osteoblasts using Cdh2(flox/flox) Osx-Cre mice. N-cadherin expression was efficiently ablated in osteoblast lineage cells as assessed by mRNA expression and immunostaining of bone sections. Basal hematopoiesis is normal in these mice. In particular, HSC number, cell cycle status, long-term repopulating activity, and self-renewal capacity were normal. Moreover, engraftment of wild-type cells into N-cadherin-deleted recipients was normal. Finally, these mice responded normally to G-CSF, a stimulus that mobilizes HSCs by inducing alterations to the stromal micro-environment. In conclusion, N-cadherin expression in osteoblast lineage cells is dispensable for HSC maintenance in mice.
Leukemia | 2014
Laura G. Schuettpelz; Joshua N. Borgerding; Matthew J. Christopher; Priya K. Gopalan; Molly P. Romine; Angela Herman; Jill Woloszynek; Adam M. Greenbaum; Daniel C. Link
Recent studies demonstrate that inflammatory signals regulate hematopoietic stem cells (HSCs). Granulocyte colony-stimulating factor (G-CSF) is often induced with infection and has a key role in the stress granulopoiesis response. However, its effects on HSCs are less clear. Herein, we show that treatment with G-CSF induces expansion and increased quiescence of phenotypic HSCs, but causes a marked, cell-autonomous HSC repopulating defect associated with induction of Toll-like receptor (TLR) expression and signaling. The G-CSF-mediated expansion of HSCs is reduced in mice lacking TLR2, TLR4 or the TLR signaling adaptor MyD88. Induction of HSC quiescence is abrogated in mice lacking MyD88 or in mice treated with antibiotics to suppress intestinal flora. Finally, loss of TLR4 or germ-free conditions mitigates the G-CSF-mediated HSC repopulating defect. These data suggest that low-level TLR agonist production by commensal flora contributes to the regulation of HSC function and that G-CSF negatively regulates HSCs, in part, by enhancing TLR signaling.
Blood | 2011
Suparna Nanua; Mark A. Murakami; Jun Xia; David S. Grenda; Jill Woloszynek; Marie Strand; Daniel C. Link
Severe congenital neutropenia (SCN) is an inborn disorder of granulopoiesis that in many cases is caused by mutations of the ELANE gene, which encodes neutrophil elastase (NE). Recent data suggest a model in which ELANE mutations result in NE protein misfolding, induction of endoplasmic reticulum (ER) stress, activation of the unfolded protein response (UPR), and ultimately a block in granulocytic differentiation. To test this model, we generated transgenic mice carrying a targeted mutation of Elane (G193X) reproducing a mutation found in SCN. The G193X Elane allele produces a truncated NE protein that is rapidly degraded. Granulocytic precursors from G193X Elane mice, though without significant basal UPR activation, are sensitive to chemical induction of ER stress. Basal and stress granulopoiesis after myeloablative therapy are normal in these mice. Moreover, inaction of protein kinase RNA-like ER kinase (Perk), one of the major sensors of ER stress, either alone or in combination with G193X Elane, had no effect on basal granulopoiesis. However, inhibition of the ER-associated degradation (ERAD) pathway using a proteosome inhibitor resulted in marked neutropenia in G193X Elane. The selective sensitivity of G913X Elane granulocytic cells to ER stress provides new and strong support for the UPR model of disease patho-genesis in SCN.
Journal of Leukocyte Biology | 2010
Alyssa D. Gregory; Benjamin J. Capoccia; Jill Woloszynek; Daniel C. Link
There is considerable interest in the potential of cell‐based approaches to mediate therapeutic angiogenesis for acute and chronic vascular syndromes. Using a mouse model of HLI, we showed previously that adoptive transfer of a small number of donor monocytes enhanced revascularization significantly. Herein, we provide data suggesting that the BM resident monocytes sense systemic signals that influence their future functional capacity. Specifically, following induction of distant ischemia, the angiogenic capacity of BM resident monocytes is reduced markedly. We provide evidence that G‐CSF and IL‐6 represent such “conditioning” signals. Systemic levels of G‐CSF and IL‐6 are increased significantly following induction of HLI. Accordingly, BM resident monocytes from ischemic mice exhibited increased pSTAT3 and STAT3 target gene expression. Finally, G‐CSFR−/− and IL‐6−/− mice were resistant to the deleterious effects of ischemic conditioning on monocyte angiogenic potential. RNA expression profiling suggested that ischemia‐conditioned monocytes in the BM up‐regulate the well‐described M2 polarization markers Chi3l4 and Lrg1. Consistent with this observation, M2‐skewed monocytes from SHIP−/− mice also had impaired angiogenic capacity. Collectively, these data show that G‐CSF and IL‐6 provide signals that determine the angiogenic potential of BM resident monocytes.
Blood | 2004
Jill Woloszynek; Robert Rothbaum; Amy S. Rawls; Patrick Minx; Richard Wilson; Philip J. Mason; Monica Bessler; Daniel C. Link
Blood | 2006
Craig H. Mermel; Morgan L. McLemore; Fulu Liu; Shalini Pereira; Jill Woloszynek; Clifford A. Lowell; Daniel C. Link
Blood | 2007
Amy S. Rawls; Alyssa D. Gregory; Jill Woloszynek; Fulu Liu; Daniel C. Link
Experimental Hematology | 2011
Ghada Kunter; Jill Woloszynek; Daniel C. Link